Euroz Hartleys: World's First iPSC-Based Drug Approved
Equity research from Euroz Hartleys examines the significance of Japan's endorsement of two iPSC-derived treatments - Sumitomo Pharma's Parkinson's disease therapy and CUORiPS' ReHeart cardiac muscle cell sheets for severe heart failure - marking the world's first medical products based on induced pluripotent stem cell technology to receive regulatory approval.
The report analyses how these regulatory milestones validate the iPSC technology underpinning Cynata's Cymerus™ platform and their implications for our development pathway as we approach dual Phase 2 and Phase 3 trial readouts in Q2 2026.
Euroz Hartleys maintains Speculative Buy recommendation with A$0.90 price target.
Published 20 February 2026 by Research Analyst Seth Lizee.
0
likes
•
0
questions
•
0
company answers
Ask a question
Your question will be sent privately to Cynata Therapeutics. The company may choose to make this question public.
Investor Q&As
Start the conversation
Ask Cynata Therapeutics a question about this update.